Ulugbek Khudayberdievich Mirzaev

Dr. Ulugbek Khudayberdievich Mirzaev

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2025 in BMC Infectious Diseases
Verified
Journal Article
Open access
MOMalokhat Palvannazirovna Oltieva
Malokhat Palvannazirovna Oltieva
DADilfuza Abdullaevna Alieva
Dilfuza Abdullaevna Alieva
SASitorabonu Bahodir Kizi Abdusattorova
Sitorabonu Bahodir Kizi Abdusattorova
ISIroda Pulatovna Sharipova
Iroda Pulatovna Sharipova
JJJasur Ravshanovich Juraev
Jasur Ravshanovich Juraev
UMUlugbek Khudayberdievich Mirzaev
Ulugbek Khudayberdievich Mirzaev
Cervical cancer imposes a substantial public health burden in Uzbekistan, yet comprehensive HPV epidemiological data are lacking. This study characterized high-risk HPV prevalence, genotype distribution, risk factors, and screening coverage in three key regions. We analyzed data from 44,497 women aged ≥ 20 years attending gynecological services in Tashkent, Andijan, and Samarkand (2021–2023). Liquid-based cytology and HPV DNA testing for 12 high-risk genotypes were performed. Sociodemographic, reproductive, behavioral, and clinical variables were collected via standardized questionnaires and examination. Multivariable logistic regression identified associated factors of high-risk HPV infection. High-risk HPV was detected in 3,779 women (8.5%), with regional prevalence of 9.2% in Andijan, 8.8% in Tashkent, and 6.5% in Samarkand. Mixed genotype infections comprised 52.8% of cases; HPV-16/18 accounted for 41.1%. Among HPV-positive women undergoing cytology (n = 2,275), 64.1% had negative findings, 14.7% LSIL, 8.4% ASC-US, 6.9% HSIL, 5.1% ASC-H, 0.5% atypical glandular cells, and 0.3% carcinoma. Independent predictors of HPV infection included younger age, single marital status, lower parity, abortion history, and hormonal contraception (all p < 0.05). Foamy vaginal discharge was a significant clinical predictor (adjusted OR 1.53; p < 0.01). Uzbekistan exhibits an intermediate high-risk HPV burden, dominated by vaccine-preventable genotypes, and low screening coverage. Targeted outreach to identified high-risk groups—by age, reproductive history, and clinical features—will optimize resource allocation. These data support accelerated progress toward WHO elimination targets in Uzbekistan. The online version contains supplementary material available at 10.1186/s12879-025-12096-7.

30 May 2024 in The Journal of Infection in Developing Countries
Verified
Journal Article
Open access
PDF file
NINargiz Ibadullaeva
Nargiz Ibadullaeva
AKAziza Khikmatullaeva
Aziza Khikmatullaeva
UMUlugbek Khudayberdievich Mirzaev
Ulugbek Khudayberdievich Mirzaev
NKNataliya Kan
Nataliya Kan
MBMarina Bobkova
Marina Bobkova
EMErkin Musabaev
Erkin Musabaev
Introduction: The severity and clinical outcome of COVID-19 depend on virus-specific factors and the host's inflammatory response. Identifying biomarkers of severe COVID-19 is a crucial condition and predicts disease severity. Methodology: This study enrolled a total of 167 patients with COVID-19. These patients were categorized into three groups based on the severity of the disease: moderate course - 78 individuals, severe course - 52 individuals, and extremely severe course - 37 individuals. We analyzed chemokines (IP-10, CXCL9, CCL17) and cytokine IL28B levels using the enzyme immunoassay (EIA) method. Results: CXCL9 levels were increased in severe and extremely severe cases compared to moderate ones. The CCL17 chemokine demonstrated significant elevation in severe cases. However, there was no significant difference in the level of IP-10, and IL28B in the compared groups. Conclusions: Our findings suggest that CXCL9 and CCL17 chemokines could be used as biomarkers to assess the clinical status of patients with COVID-19 and can relate to disease severity. These biomarkers could aid in identifying patients at high risk for severe disease and help guide clinical decision-making for the effective management of COVID-19.

21 August 2025 in European Journal of Public Health
Verified
Journal Article
Open access
UIUmed Yusupovich Ismoilov
Umed Yusupovich Ismoilov
EMErkin Isakovich Musabaev
Erkin Isakovich Musabaev
AKAziza Saidullaevna Khikmatullaeva
Aziza Saidullaevna Khikmatullaeva
NINargiz Sapievna Ibadullaeva
Nargiz Sapievna Ibadullaeva
NKNataliya Georgiyevna Kan
Nataliya Georgiyevna Kan
UMUlugbek Khudayberdievich Mirzaev
Ulugbek Khudayberdievich Mirzaev
Uzbekistan initiated a nationwide screening program for viral hepatitis B (HBV) and C (HCV) in response to the global call for viral hepatitis elimination by 2030. This study aimed to assess HBV and HCV prevalence among the general population, provide treatment for diagnosed cases, and evaluate the effectiveness of direct-acting antiviral (DAA) therapy for HCV. From July 2022 to June 2024, 1 048 575 individuals aged 1-95 years were screened at local healthcare facilities using rapid immunochromatographic tests for hepatitis B surface antigen (HBsAg) and antibodies against hepatitis C virus (anti-HCV). Positive cases underwent confirmatory testing and were linked to care. HCV RNA-positive patients were assessed for DAA treatment eligibility. Overall HBsAg prevalence was 2.89% and anti-HCV prevalence was 3.52%. HBV prevalence decreased from 3.25% in those born before 2000 to 0.77% in those born after (P < .01), reflecting the impact of the national HBV vaccination program. Of 32 132 anti-HCV positive individuals, 20 039 (62.4%) were confirmed HCV RNA positive. Among these, 18 327 were eligible for DAA treatment. The majority received a 12-week treatment course, while 2126 (11%) with advanced liver fibrosis received a 24-week regimen. The sustained virological response rate was high, with only 1.17% of patients with advanced fibrosis and 0.96% without advanced fibrosis failing to achieve viral clearance. This large-scale study demonstrates the effectiveness of Uzbekistan’s HBV vaccination program and the success of DAA treatment in achieving high cure rates for HCV. The study provides crucial data to guide public health strategies for combating viral hepatitis in Uzbekistan and progressing towards the World Health Organization's 2030 elimination targets.

3 March 2026 in Public Health
Verified
Journal Article
Open access
KOKhasanjon Odilov
Khasanjon Odilov
OCOdgerel Chimed-Ochir
Odgerel Chimed-Ochir
YYYui Yumiya
Yui Yumiya
HMHanako Murayama
Hanako Murayama
AFAmi Fukunaga
Ami Fukunaga
TKTatsuhiko Kubo
Tatsuhiko Kubo
To assess cardiovascular disease (CVD) risk among adults in Uzbekistan using the UZ-SPEED non-communicable disease (NCD) screening tool and to examine its associations with modifiable risk factors. Pilot study. This study was conducted from June to July 2024 and examined a convenience sample of 1735 adults aged 40 to 74 years in four diverse regions of Uzbekistan. Demographic, behavioral, and clinical data were collected by using an adapted version of the Japanese Surveillance in Post-Extreme Emergencies and Disasters (J-SPEED) - UZ-SPEED NCD tool. CVD risk was assessed using non-laboratory-based and laboratory-based WHO risk charts. Logistic regression analysis with correction for confounding was used to identify factors associated with a high risk of CVD (≥10%). Overall, 19.6% of participants had a high risk of CVD based on non-laboratory variables, and 16.8% had a high risk based on laboratory variables. Alcohol use was strongly associated with the risk of CVD. Unexpectedly, frequent consumption of sugary foods showed inverse associations with CVD risk, likely due to self-reporting bias or the unclearness of the questions. Consumption of fatty foods and obesity was associated with increased risk of CVD. We also identified geographical disparities; participants from Namangan region had a greater risk of CVD. These findings highlight the need for more precise measurement of dietary habits, particularly the consumption of sugary foods, when screening for CVD. The UZ-SPEED NCD tool facilitated the timely collection and analysis of standardized data in a setting with limited resources.

17 August 2026 in Infectious Diseases of Poverty
Verified
Journal Article
Open access
PDF file
EMErkin Isakovich Musabaev
Erkin Isakovich Musabaev
MKMalika Erkinovna Khodjaeva
Malika Erkinovna Khodjaeva
AKAziza Saydullaevna Khikmatullaeva
Aziza Saydullaevna Khikmatullaeva
NINargiz Sapievna Ibadullaeva
Nargiz Sapievna Ibadullaeva
FSFatima Shokir Kizi Shodieva
Fatima Shokir Kizi Shodieva
UMUlugbek Khudayberdievich Mirzaev
Ulugbek Khudayberdievich Mirzaev
Background: Uzbekistan faces a substantial burden of hepatitis B and D virus (HBV and HDV) infections despite implementing universal hepatitis B vaccination in 1998. Regional variation in disease distribution and contemporary transmission dynamics remain inadequately characterized. Our objective was to evaluate the geographically stratified prevalence of HBV and HDV, while also identifying the key risk factors fueling transmission within the adult population of Uzbekistan. Methods: We conducted a nationwide cross-sectional study of 10,552 adults across seven regions of Uzbekistan from July 2022 to June 2024. Participants were selected using stratified random sampling from a parent cohort of 1,048,575 individuals. Serological testing included hepatitis B surface antigen (HBsAg), antibodies to hepatitis B core antigen (anti-HBc), anti-HDV antibodies, and viral RNA detection. Multivariate logistic regression identified independent risk factors for HBV and HDV infections. Results: Overall HBsAg prevalence was 4.7% (95% CI : 4.3–5.1%), with substantial geographic heterogeneity ranging from 3.2% in Tashkent to 6.3% in Bukhara. Among HBsAg-positive individuals, 68.1% had detectable HBV DNA and 12.7% had HDV superinfection. HDV RNA prevalence among HBV DNA-positive individuals ranged from 2.5% to 23.7% across regions. Age-cohort analysis demonstrated vaccination program impact, with older unvaccinated adults bearing disproportionate disease burden. Female sex associated with 31% lower odds of chronic HBsAg carriage. Married status, healthcare-associated exposures, and body piercings correlated with increased anti-HBc positivity. Remarkably, sharing personal hygiene items showed striking HDV-specific association (a O R 2.34, 95% CI : 1.16–4.74; P = 0.02) but no association with HBV markers, suggesting distinct transmission pathways for HDV superinfection. Conclusions: Persistent HBV burden with notable regional clustering and HDV superinfection necessitates targeted interventions. The identification of personal hygiene item sharing as a specific HDV transmission route provides an actionable household-level prevention target. Intensified screening and treatment of unvaccinated adults remain critical for hepatitis elimination efforts.

20 November 2025 in Infectious Medicine
Verified
Journal Article
Open access
AKAziza Saydullaevna Khikmatullaeva
Aziza Saydullaevna Khikmatullaeva
KBKrestina Stepanovna Brigida
Krestina Stepanovna Brigida
NМNargiza Mirzakhidovna Мirrakhimova
Nargiza Mirzakhidovna Мirrakhimova
MАMuazzam Alievna Аbdukadirova
Muazzam Alievna Аbdukadirova
NINargiz Sapievna Ibadullaeva
Nargiz Sapievna Ibadullaeva
UMUlugbek Khudayberdievich Mirzaev
Ulugbek Khudayberdievich Mirzaev
Chronic viral hepatitis remains a significant global health burden, with accurate assessment of liver fibrosis being crucial for patient management. This study aimed to evaluate the diagnostic accuracy of non-invasive tests (NITs) for liver fibrosis assessment in patients with chronic hepatitis B (HBV), hepatitis B and D co-infection (HBV + HDV), and hepatitis C (HCV) infections. A prospective study was conducted on 78 patients with chronic viral hepatitis (22 HBV, 34 HBV + HDV, 22 HCV). Participants underwent magnetic resonance elastography (MRE), transient elastography (TE), and serum biomarker testing (APRI, FIB-4, PIIINP, COL4). MRE was used as the reference standard for liver fibrosis staging. Transient elastography demonstrated the highest diagnostic accuracy for detecting advanced liver fibrosis across all etiologies (AUC 0.95, cutoff 10.2 kPa). The performance of serum biomarkers varied among different viral hepatitis etiologies. In chronic hepatitis B, APRI and FIB-4 showed moderate performance (AUC 0.64), while PIIINP and COL4 demonstrated poor diagnostic accuracy. In HBV + HDV co-infection, all markers showed moderate performance. In chronic hepatitis C, COL4 demonstrated excellent diagnostic accuracy (AUC 0.93), while FIB-4 and APRI showed moderate performance. This study highlights the complex relationship between viral hepatitis etiologies and the performance of non-invasive fibrosis tests. While TE demonstrates high accuracy across all groups, the utility of serum biomarkers varies significantly. These findings underscore the importance of considering the specific viral etiology when selecting and interpreting NITs for liver fibrosis assessment in chronic viral hepatitis patients.